ActRⅡB fusion protein and its preparation method and application
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- SHENYANG SUNSHINE PHARMA CO LTD
- Filing Date
- 2025-01-15
- Publication Date
- 2026-07-17
AI Technical Summary
Existing treatments for anemia in MDS have limited efficacy and numerous adverse reactions, especially for low-risk MDS patients. There is an urgent need for more effective and safer inhibitors targeting the TGF-β superfamily signaling pathway to alleviate anemia symptoms.
Develop an ActRIIB fusion protein containing a specific amino acid-substituted ActRIIB extracellular domain and IgG Fc, which inhibits the SMAD2/3 signaling pathway through a ligand trapping mechanism, promotes erythrocyte maturation, and increases erythrocyte levels.
It significantly increases red blood cell levels in a mouse anemia model, outperforming the existing drug rotezip, and has better therapeutic efficacy and safety, making it suitable for the treatment of various anemia-related diseases.
Smart Images
Figure BDA0005244246850000141 
Figure BDA0005244246850000151 
Figure BDA0005244246850000161